Characterization of genomic alterations of cytarabine-resistant AML cells with FLT3-ITD mutation

被引：0
|
作者：
Yen, J. H. [1 ]
Chen, Z. A. [2 ]
Lin, L. I. [3 ]
Chen, P. Y. [4 ]
机构：
[1] Tzu Chi Univ, Dept Mol Biol & Human Genet, Hualien, Taiwan
[2] Tzu Chi Univ, Dept Life Sci, Hualien, Taiwan
[3] Natl Taiwan Univ, Dept Clin Lab Sci & Med Biotechnol, Taipei, Taiwan
[4] Hualien Tzu Chi Hosp, Ctr Med Genet, Hualien, Taiwan
来源：
EUROPEAN JOURNAL OF HUMAN GENETICS | 2019年 / 27卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
P13.06B
引用
收藏
页码：1608 / 1608
页数：1
相关论文
共 50 条
  • [31] Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
    H Wu
    C Hu
    A Wang
    E L Weisberg
    W Wang
    C Chen
    Z Zhao
    K Yu
    J Liu
    J Wu
    A Nonami
    L Wang
    B Wang
    R M Stone
    S Liu
    J D Griffin
    J Liu
    Q Liu
    Leukemia, 2016, 30 : 754 - 757
  • [32] Novel Small Molecule FLT3 Inhibitors for the Treatment of FLT3-ITD AML
    Melgar, Katelyn
    Walker, MacKenzie
    Jiang, Jian-kang
    Wilson, Kelli
    Mulloy, James C.
    Thomas, Craig J.
    Starczynowski, Daniel T.
    BLOOD, 2015, 126 (23)
  • [33] Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
    Wu, H.
    Hu, C.
    Wang, A.
    Weisberg, E. L.
    Wang, W.
    Chen, C.
    Zhao, Z.
    Yu, K.
    Liu, J.
    Wu, J.
    Nonami, A.
    Wang, L.
    Wang, B.
    Stone, R. M.
    Liu, S.
    Griffin, J. D.
    Liu, J.
    Liu, Q.
    LEUKEMIA, 2016, 30 (03) : 754 - 757
  • [34] FLT3-ITD Activation Mediates Resistance to the BCL-2 Selective Antagonist, Venetoclax, in FLT3-ITD Mutant AML Models
    Mali, Raghuveer Singh
    Lasater, Elisabeth A.
    Doyle, Kelly
    Malla, Ritu
    Boghaert, Erwin
    Souers, Andrew
    Leverson, Joel D.
    Sampath, Deepak
    BLOOD, 2017, 130
  • [35] Developing dual FLT3/MNK inhibitors to overcome sorafenib resistance in FLT3-ITD AML cells
    Zhao, Linxiang
    Zuo, Shuwei
    Xing, Kun
    Yue, Xiaoshuang
    Zhang, Huimin
    Zhang, Jingyi
    Waxman, Samuel
    Jing, Yongkui
    CANCER RESEARCH, 2024, 84 (06)
  • [36] Role of Enhanced Autophagy in Resistance of FLT3-ITD AML Stem Cells to FLT3 TKI Treatment
    Qiu, Shaowei
    Paterson, Andrew J.
    Abraham, Ajay
    He, Jianbo
    Shah, Mansi
    Agarwal, Puneet
    Mullen, Amanda K.
    Li, Hui
    Harris, Mason W.
    Anderson, Nicholas R.
    Bhatia, Ravi
    BLOOD, 2018, 132
  • [37] Influence of IDH on FLT3-ITD status in newly diagnosed AML
    Boddu, P.
    Takahashi, K.
    Pemmaraju, N.
    Daver, N.
    Benton, C. B.
    Pierce, S.
    Konopleva, M.
    Ravandi, F.
    Cortes, J.
    Kantarjian, H.
    DiNardo, C. D.
    LEUKEMIA, 2017, 31 (11) : 2526 - 2529
  • [38] A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment
    Long, Jun
    Chen, Xinjie
    Shen, Yan
    Lei, Yichen
    Mu, Lili
    Wang, Zhen
    Xiang, Rufang
    Gao, Wenhui
    Wang, Lining
    Wang, Ling
    Jiang, Jieling
    Zhang, Wenjun
    Lu, Huina
    Dong, Yan
    Ding, Yi
    Zhu, Honghu
    Hong, Dengli
    Sun, Yi Eve
    Hu, Jiong
    Liang, Aibin
    CELL REPORTS MEDICINE, 2023, 4 (11)
  • [39] Improved survival in AML patients with a high FLT3-ITD mutation rate after allogeneic transplantation
    Ehninger, G.
    Bornhaeuser, M.
    Kramer, M.
    Roellig, C.
    Wandt, H.
    Haenel, M.
    Einsele, H.
    Aulitzky, W.
    Schmidt, N.
    Berdel, W.
    Stelljes, M.
    Baldus, C.
    Mackensen, A.
    Platzbecker, U.
    Schaich, M.
    Thiede, C.
    Ho, A.
    Schetelig, J.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S3 - S3
  • [40] Influence of FLT3-ITD Mutation and Length on the Treatment Response and Prognosis in Cytogenetically Normal AML Patients
    Jiang, Xuejie
    Yin, Changxin
    Sun, Junya
    Cheng, Jiaying
    Wang, Qiang
    Yu, Guopan
    Jiang, Ling
    Xu, Dan
    Liu, Xiaoli
    Feng, Ru
    Liu, Qifa
    BLOOD, 2018, 132
12345